Down‐regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objective: High mobility group box chromosomal protein 1 (HMGB‐1) is an endogenous nuclear protein that can be translocated to the cytoplasm and then released extracellularly. It can induce tumor necrosis factor and interleukin‐1 production in myeloid cells. Increased expression of these 2 cytokines has been observed in muscle tissue of patients with polymyositis (PM) and dermatomyositis (DM). The present study was therefore undertaken to investigate how HMGB‐1 is expressed in muscle tissue of patients with myositis and, if so, whether such expression is modulated by prednisolone therapy. Methods: Muscle biopsy specimens from 5 patients with PM and 4 patients with DM, obtained before and 3–6 months after initiation of prednisolone therapy, were assessed by conventional microscopic evaluation and computerized image analysis, and HMGB‐1 expression was investigated by immunohistochemical staining. Muscle biopsy specimens from 7 healthy controls were also studied. Results: Cytoplasmic HMGB‐1 expression was detected in infiltrating rounded mononuclear cells, vascular endothelial cells, and muscle fibers of PM and DM patients. Extracellular staining surrounding the inflammatory cells was also observed. After treatment with high‐dose prednisolone, cytoplasmic and extracellular HMGB‐1 expression was significantly reduced, coinciding mainly with a decreased number of infiltrating inflammatory cells. Cytoplasmic HMGB‐1 expression was still evident in endothelial cells and muscle fibers. No HMGB‐1 expression was observed in muscle tissue from healthy controls. Conclusion: The cytoplasmic and extracellular distribution of HMGB‐1 in muscle tissue may indicate an important role of this proinflammatory molecule in the pathogenesis of PM and DM. Furthermore, our findings indicate that systemically administered high‐dose corticosteroids selectively down‐regulate aberrant expression of HMGB‐1 in mononuclear inflammatory cells in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221
Anti-inflammatory Actions of Glucocorticoids: Molecular Mechanisms
Barnes, P. J. (1998) · Clinical Science · doi:10.1042/cs0940557 · Cited by 1,591
The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin
Hori, O., Brett, J., Slattery, T., Cao, R., Zhang, J., Chen, J. X., Nagashima, M., Lundh, E. R., Vijay, S., Nitecki, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25752 · Cited by 1,151
Cited by
HMGB1 is a therapeutic target for sterile inflammation and infection
Andersson, U., & Tracey, K. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101323 · Cited by 1,437
“Glucocorticoid treatment of patients with chronic myositides causes reduced expression of HMGB1 in muscle tissue in association with clinical improvement (82).”
BackgroundSelf-citationKang, R., Chen, R., Zhang, Q., Hou, W., Wu, S., Cao, L., Huang, J., Yu, Y., Fan, X.-G., Yan, Z., et al. (2014) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.05.001 · Cited by 956
HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease
Harris, H. E., Andersson, U., & Pisetsky, D. S. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.222 · Cited by 689
Self-citationThe Role of HMGB1 in the Pathogenesis of Inflammatory and Autoimmune Diseases
Magna, M., & Pisetsky, D. S. (2014) · Molecular Medicine · doi:10.2119/molmed.2013.00164 · Cited by 358
An overview of polymyositis and dermatomyositis
Findlay, A. R., Goyal, N. A., & Mozaffar, T. (2015) · Muscle & Nerve · doi:10.1002/mus.24566 · Cited by 259
Metadata
- Authors
- Ulfgren, A., Grundtman, C., Borg, K., Alexanderson, H., Andersson, U., Harris, H. E., & Lundberg, I. E.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2004-05
- Volume
- 50
- Issue
- 5
- Pages
- 1586-1594
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2063601772
- Cited by
- 113
- References
- 3
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Down‐regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. https://app.cochat.ai/papers/10.1002/art.20220
- The paper
- Ulfgren, A., Grundtman, C., Borg, K., Alexanderson, H., Andersson, U., Harris, H. E., & Lundberg, I. E. (2004). Down‐regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis & Rheumatism. https://doi.org/10.1002/art.20220
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.